Related Experiment Video
Updated: Jul 5, 2025
12:52
Isolation and Flow Cytometric Analysis of Glioma-infiltrating Peripheral Blood Mononuclear Cells
Published on: November 28, 2015
15.8K
Expression of Interleukin-13 Receptor Alpha 2 in Brainstem Gliomas
Xiaoou Li1,2, Xiong Xiao1,2, Yi Wang1,3
1Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing 100070, China.
Cancers
|January 11, 2024
Summary
Interleukin-13 receptor alpha 2 (IL13Ra2) is widely expressed in brainstem gliomas (BSG), correlating with aggressive markers and poorer survival. Targeting IL13Ra2 may offer therapeutic benefits for specific BSG patient groups.
Area of Science:
- Neuro-oncology
- Molecular pathology
- Cancer therapeutics
Background:
- Brainstem glioma (BSG) is an aggressive brain tumor with limited therapeutic options.
- Interleukin-13 receptor alpha 2 (IL13Ra2) is a transmembrane protein implicated in various cancers.
- Understanding IL13Ra2 expression and its role in BSG is crucial for developing targeted therapies.
Purpose of the Study:
- To investigate IL13Ra2 expression in brainstem glioma (BSG) samples.
- To correlate IL13Ra2 expression with key tumor markers, cellular functions, and patient prognosis.
- To evaluate the therapeutic potential of targeting IL13Ra2 in BSG.
Main Methods:
- Multiplex immunofluorescence analysis of 80 BSG tumor samples for IL13Ra2, H3.3K27M, CD133, Ki67, HLA-1, and CD4.
- Survival analysis using Kaplan-Meier and Cox regression models on 66 patients.
- RNA-Seq analysis of 98 patients for differential gene expression, Gene Ontology (GO) enrichment, and ssGSEA.
Main Results:
- IL13Ra2 expression was detected in nearly all BSG patients, with 45% showing elevated levels (>20%).
- Higher IL13Ra2 levels correlated significantly with H3.3K27M mutations, increased proliferation (Ki67), and tumor stemness (CD133).
- Elevated IL13Ra2 expression (>20%) was associated with shorter overall survival, though H3F3A mutations were identified as the independent prognostic factor.
Conclusions:
- Widespread IL13Ra2 expression in BSG, especially in H3F3A-mutant tumors, is linked to aggressive tumor characteristics.
- IL13Ra2 represents a promising therapeutic target for BSGs, particularly for patients with H3K27M mutations, DIPGs, and WHO Grade IV gliomas.
- Targeting IL13Ra2 may hold significant therapeutic potential for specific, high-risk BSG subgroups.
